The Patent Finder

Accutar Biotechnology Inc.

11 patents currently held · Updated Nov 17, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Dec 2038
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jun 30, 2027
    The maintenance fee for Dual inhibitors of PARP1 and CDK (US 10,519,136) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,519,136Dual inhibitors of PARP1 and CDK
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,923,214Neural network for predicting drug property
In force (reinstated)
 · From the USPTO record
In force (reinstated)From the USPTO record
US 10,800,770Novel Chroman Derivatives Having Estrogen Receptor Degradation Activity and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,261,178Novel Chroman Derivatives Having Estrogen Receptor Degradation Activity and Uses Thereof
In force
 · Medium confidence
In forceMedium confidence
US 10,836,749Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,642,342Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,535,606Novel Substituted QUINOLINE-8-Carbonitrile Derivatives with Androgen Receptor Degradation Activity and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,521,712Computational method for classifying and predicting ligand docking conformations
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,530,222Substituted Pyrrolopyrimidine and Pyrazolopyrimidine as Bruton's Tyrosine Kinase (BTK) Degraders
In force
 · High confidence
In forceHigh confidence
US 12,331,061Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 4 patents in force now held by others · 9 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 5 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited